S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.

Bergenfelz, Caroline; Gaber, Alexander; Allaoui, Roni; Mehmeti, Meliha; Jirström, Karin; Leandersson, Tomas; Leandersson, Karin

Published in:
British Journal of Cancer

DOI:
10.1038/bjc.2015.346

2015

Citation for published version (APA):
Bergenfelz, C., Gaber, A., Allaoui, R., Mehmeti, M., Jirström, K., Leandersson, T., & Leandersson, K. (2015). S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. British Journal of Cancer, 113(8), 1234-1243. DOI: 10.1038/bjc.2015.346
S100A9 expressed in ER−PgR− breast cancers induces inflammatory cytokines and is associated with an impaired overall survival

Caroline Bergenfelz¹, Alexander Gaber², Roni Allaoui¹,⁴, Meliha Mehmeti¹,⁴, Karin Jirström², Tomas Leanderson³ and Karin Leandersson*,¹

¹Center for Molecular Pathology, Department of Translational Medicine, Lund University, Lund, Sweden; ²Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden and ³Division of Immunology, Department of Experimental Medicine, Lund University, Lund, Sweden

Background: Breast cancer is the most common cancer form among women today. Depending on hormone receptor status, breast cancers are divided into different subtypes with vastly varying prognosis. S100A9 is a calcium-binding protein that is associated with inflammation and expressed not only in myeloid cells but also in some tumours. The role for S100A9 in the malignant cells is not well characterised; however, previous studies have shown that the protein could have important immune-modulating properties.

Methods: Using a human breast cancer cohort consisting of 144 tumour samples and in vitro analysis of human breast cancer cell lines, we investigated the expression and function of S100A9 in human breast cancer.

Results: We show that S100A9 expression in breast cancer correlated with the ER−PgR− breast tumour subtype (P<0.001) and with Ki67 (P=0.024) and was expressed both in the malignant cells and in the tumour-infiltrating anti-inflammatory CD163+ myeloid cells (P<0.001). Stromal expression of S100A9 also correlated to nodal stage, tumour size and Her2 positivity. Within the ER−PgR− subgroup, all Her2+ and EGFR+ tumours expressed S100A9 in the cytoplasm. Both cytoplasmic staining in the malignant cells as well as stromal S100A9 expression in myeloid cells correlated with a decreased overall survival in breast cancer patients. Furthermore, rS100A9 homodimers induced expression of pro-inflammatory cytokines (IL-6, IL-8 and IL-1β) in a TLR4- and EGFR-dependent manner in human breast cancer cells in vitro.

Conclusion: We suggest that S100A9 could be viewed as a novel therapeutic target for patients with ER−PgR− breast cancers.

Breast cancer is the most common cancer form among women (Kamangar et al, 2006). Clinical breast cancer classification is partly based on hormone receptor status of oestrogen receptor (ER), progesterone receptor (PgR) and Her2 receptor (Sorlie et al, 2001; Allred et al, 2004; Schnitt, 2010). Depending on hormone receptor status, breast cancers are divided into different subtypes with vastly varying prognosis and treatment strategies. ER− breast cancer patients have the best prognosis. In contrast, hormone receptor-negative breast cancers, that is, ER−, PgR− and Her2− (also denoted triple-negative (TN) subtype) have the worst prognosis (Schnitt, 2010). Although there are numerous treatment options for hormone receptor-positive patients, there are inadequate options for TN breast cancer patients (Schnitt, 2010). Therefore, novel treatment options are urgently needed for this breast cancer subgroup particularly.

Cancer cells are dependent on an uncontrolled and indefinite cell division. This can be mediated by different mutations and mechanisms supporting the cancer cell proliferation. Two typical
growth factor receptors that are commonly upregulated in breast cancers are the epidermal growth factor receptor (EGFR/ERBB1) and human epidermal growth factor 2 receptor (HER2/ERBB2). These are also often mutated to generate a constitutive activation and thus enhanced cell proliferation. The expression of EGFR and HER2 in breast cancers is generally not beneficial for survival (Hanahan and Weinberg, 2000), although patients with HER2+ tumours have a slightly better prognosis owing to specialised treatment options (Schnitt, 2010).

S100A9 is a calcium-binding protein involved in inflammatory processes (Lagasse and Clerc, 1988; Zwaldo et al, 1988; Edgeworth et al, 1991; Hessain et al, 1993; Heizmann et al, 2002; Marenczyk et al, 2004) and the protein can form homodimers or heterodimers with S100A8. S100A9 is mainly expressed in neutrophils and myeloid cells where it induces inflammatory cascades. Neutrophils primarily express S100A9/S100A8 heterodimers, thought to be involved in inflammatory diseases. In myeloid cells, it is believed that S100A9 signals as a Ca2+-and Zn2+-dependent damage-associated molecular pattern, via Toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE) whereby activation of NFκB is induced (Roth et al, 2003; Sunahori et al, 2006; Benedyk et al, 2007; Sinha et al, 2008; Riva et al, 2012). S100A9 has a strong immunosuppressive function in tumour-infiltrating myeloid-derived suppressor cells (MDSCs) (Ostrand-Rosenberg and Sinha, 2009). This is in sharp contrast to the role for S100A9 in tumour-infiltrating neutrophils (Yui et al, 2003). Furthermore, S100A9 has been shown to act as a chemo-attractant for immunosuppressive cells such as MDSCs or anti-inflammatory myeloid cells in tumours (Srikrishna et al, 2001; Ostrand-Rosenberg and Sinha, 2009). The protein expression of S100A9 in breast cancer has previously been studied in smaller cohorts (Arai et al, 2004; Cross et al, 2005; Arai et al, 2008) and in a large protein profiling study performed on breast cancers (Goncalves et al, 2008) where only cytoplasmic S100A9 expression in the malignant cells was scored. The functional role of the protein in malignant breast epithelial cells is controversial (Arai et al, 2004, 2008; Moon et al, 2008; Yin et al, 2013; Cormier et al, 2014; Gumireddy et al, 2014; Bresnick et al, 2015).

We have previously shown that anti-inflammatory myeloid cells are preferentially expressed in the tumour stroma of TN breast tumours (Medrek et al, 2012). The reason to this preferential location is unknown and one factor could be expression of chemo-attractants, such as S100A9. In this study, we investigated the expression and localisation pattern of S100A9 in 144 breast tumours and found a strong correlation not only to ER− PgR− tumours (irrespective of S100A9 localisation) and to the proliferation marker Ki67 (cytoplasmic and stromal localisation) but also to the presence of anti-inflammatory myeloid cells. Stromal S100A9 localisation further correlated to parameters such as larger tumour size, Her2 positivity and nodal stage. Within the ER− PgR− subgroup, all Her2+ and EGFR+ tumours expressed S100A9. This was further supported by gene expression profile analyses where ER, PgR, Her2 or EGFR mRNA expression strongly correlated with S100A9 expression, respectively. Also, stimulation with rEGF induced S100A9 mRNA expression. When breast cancer cell lines were stimulated with homodimers of rS100A9, induction of pro-inflammatory cytokines (IL-6, IL-8 and IL-1β) was observed in a TLR4-dependent manner. This was not observed when stimulating with S100A9/A8 heterodimers. Importantly, cytoplasmic staining of S100A9 in the malignant cells, as well as in stromal myeloid cells, correlated with an impaired overall survival in breast cancer patients. We suggest that S100A9 should be viewed as a potential therapeutic target for patients with ER− PgR− breast cancers.

### Material and Methods

#### Cell culture.

The human breast cancer cell lines MCF-7, T47-D, MDA-MB-231 and MDA-MB-468 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Biosera, Bouxens, France), 1% sodium pyruvate, 1% HEPES and penicillin/streptomycin (100 U ml−1 and 100 μg ml−1, respectively). CAMA-1 was cultured in MEM/EBOSS supplemented with 10% FBS and penicillin/streptomycin, and SKBR3 was cultured in McCoy’s 5A medium (without phenol red supplemented) with 10% FBS and penicillin/streptomycin. All cell lines were from ATCC (Wesel, Germany). Media and supplements were purchased from Thermo Scientific HyClone (South Logan, UT, USA) unless otherwise stated.

All stimulations were performed for a total of 20h. Recombinant human S100A9 (rS100A9) and S100A9/S100A8 was a gift from Active Biotech AB (Lund, Sweden), and a detailed description on endotoxin-free S100A9 and S100A8/S9 generation, purification, bioactivity and binding has been published previously (Bjork et al, 2009; Riva et al, 2012; Bjork et al, 2013; Riva et al, 2013). Both S100A9 and S100A8/S9 were used at a concentration of 10 μg ml−1. As proper S100A9 homodimer activity and binding of S100A9 to its receptors requires the presence of calcium and zinc (Bjork et al, 2009; Markowitiz and Carson, 2013), cells were pretreated with 10 μM ZnCl2 ≥15 min prior stimulation with rS100A9 at the indicated concentrations. All purchased media contained Ca2+ (≥ 200 μM).

#### Compounds and cytokine analysis.

Antibodies used for S100A9 western blotting (WB), immunoprecipitation (IP) and IHC were Calgranulin B (clone MRP 1H9; Santa Cruz, Dallas, TX, USA), Lamin B (clone C-20; Santa Cruz) and Actin (clone C-4; MP Biomedicals, Solon, OH, USA). Supernatants from rS100A9-stimulated or siRNA-transfected cells were harvested and analysed using human inflammatory cytokine cytometric bead array (BD Biosciences, San Diego, CA, USA) or quantikine human CXCL8/IL-8 immunoassay (R&D Systems, Minneapolis, MN, USA) according to the manufacturers’ instructions. IL-10 and IL-12 were largely undetectable and hence excluded in this study.

#### Tissue microarray.

The large breast cancer cohort analysed in this study consists of 144 patients diagnosed with invasive breast cancer at Skåne University Hospital, Malmö, Sweden between 2001 and 2002. The cohort and TMA has previously been described in detail (Elkabetz et al, 2011; Gronberg et al, 2011; Svensson et al, 2011) and (Medrek et al, 2012).

#### Ethical considerations.

Ethical permit was obtained from the local ethical committee at Lund University (Dnr 447/07). Signed informed consent was not collected but the patients were offered to opt out.

#### Immunohistochemistry.

Four-μm-thick TMA sections were mounted onto glass slides and deparaffinised followed by antigen retrieval using the PT-link system (DAKO, Glostrup, Denmark) and stained in a Autostainer Plus (DAKO) with the EnVisionFlex High pH-kit (DAKO). Antibodies used were: anti-Calgranulin B (S100A9; clone MRP 1H9 dilution 1 : 200; Santa Cruz), anti-CD163 (10D6 dilution 1 : 250; Novocastra, GMBH, Nülschö, Germany), and anti-CD68 (dilution 1 : 1500; DAKO).

#### Gene expression profile array.

Correlations between S100A9 and ER, PgR, EGFR or Her2 in a separate data set (Tumour breast cancer proteomics array) were analysed by microarray analysis and visualisation platform (http://r2.amcc.nl).

#### Quantitative real-time PCR (qRT–PCR).

Total RNA was extracted using the RNeasy Plus Kit according to the manufacturer’s instructions (Qiagen, Hilden, MD, USA). Equal amounts of
RNA were used for cDNA synthesis using random hexamers and the M-MuLV reverse transcriptase enzyme (Thermo Scientific). qRT–PCR was performed in triplicates using Maxima SYBR Green/Rox (Thermo Scientific) according to the manufacturer’s instructions. qRT–PCR analysis was performed on the Mx3005P QPCR system (Agilent Technologies, Santa Clara, CA, USA) and the relative mRNA expression was normalised to YWHAZ, UBC and SDHA and calculated using the comparative Ct method (Vandesompele et al, 2002). For primer sequences, see Supplementary Table S1.

Transient transfections and luciferase assays. Transient siRNA transfections were performed using Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). In all, 10 nM of the following silencer select siRNA oligonucleotides were used: Silencer Select Negative Control #2, siS100A9 #1 (s12425), siS100A9 #2 (s12426), siTLR4 #1 (s14194) and siTLR4 #2 (s14195), all purchased from Ambion (Carlsbad, CA, USA). For proliferation and viability assays, the cells were re-seeded into 96-well plates after 24 h. All analyses were performed 72 h posttransfection.

For transient transfection and luciferase assays, breast cancer cells were co-transfected with a total of 0.5 μg pNFκB-luciferase (BD Biosciences) and 0.05 μg TK-renilla-luciferase (Promega, Madison, WI, USA) plasmids, w/o/wo 1 μg pDUO-MD2-hTLR4 (Invivogen, San Diego, CA, USA) plasmid or 10 nM of the respective siRNA, using Lipofectamine 2000. rS100A9 stimulation was performed 24 h posttransfection as described above. The NFκB activity was analysed using the Dual-Luciferase Reporter Assay System (Promega).

Cell proliferation and viability assays. The effects of rS100A9 or S100A9 knockdown on cell proliferation and viability was assessed using thymidine incorporation, WST-1 assay and Annexin V-staining. In all, 1 μCi [methyl-3H] thymidine was added 18 h prior to analysis, and thymidine incorporation was determined in a Microbeta Counter (PerkinElmer, Waltham, MA, USA). The WST-1 assay was performed according to the manufacturer’s recommendations (Roche Applied Science, Indianapolis, IN, USA). For Annexin V staining, cells were detached using EDTA-free trypsin (Thermo Scientific), washed twice in PBS prior to Annexin V-APC and PI staining according to the manufacturer’s instructions (BD Biosciences). The amount of viable cells was analysed using a FACSVersé (BD).

Statistics and annotation. ANOVA or Student’s t-test were used for in vitro experiments as indicated, using the Graph Pad Prism software (La Jolla, CA, USA).

Immunohistochemical S100A9 expression in TMA breast cancer tumours was estimated in fraction (percent) and intensity (0–3) separately annotated for nuclear, cytoplasmic, membrane and stromal compartments. A multiplier of percent and intensity for each core was constructed, yielding a score of 0–3, and a mean value of the two cores was used in the analyses. Spearman’s Rho and χ² test was used for comparison of CD163, CD68 and S100A9 expression. Classification and regression tree (CRT) was used for cutoff purposes, and Kaplan–Meier analysis with log rank tests were used to illustrate differences in survival. All statistical tests were two sided and P<0.05 were considered significant. Calculations were performed with IBM SPSS Statistics version 19.0 (IBM Corp, Armonk, NY, USA).

Figure 1. Analysis of S100A9 protein and mRNA expression in breast cancer cells lines. (A) The relative expression of S100A9 mRNA using Q-PCR on mRNA from the cell lines indicated. Error bars indicate s.e.m. ***P<0.001 using ANOVA test. (B) WB of immunoprecipitated (IP) cell lysates from the indicated cell lines. (C) IHC using an anti-human S100A9-specific antibody on paraffin-embedded cell pellets from the cell lines indicated. (D) WB of nuclear and cytoplasmic fractions. Nuclear extracts was controlled with the Lamin B-specific antibody. Actin shows the loading control for each lane. IHC, IP and WB antibody was the same in panels (A–C).
RESULTS

S100A9 is expressed in ER⁺PgR⁺ breast cancer cell lines expressing EGFR. To investigate the expression pattern of S100A9 in human breast cancers, we started by verifying a human specific anti-calgranulin B (S100A9) antibody (clone MRP 1H9). To this end, we first characterised the S100A9 expression pattern in six different breast cancer cell lines (MCF-7, T47D, CAMA-1 (all three ER⁺PgR⁺) and MDA-MB-231 (TN), MDA-MB-468 (TN EGFR⁺⁺), SKBR3 (ER⁻ PgR⁻ Her2⁺)), by using Q-PCR, WB and IHC of paraffin-embedded cell pellets (Figure 1). The endogenous mRNA levels of S100A9 were compared using Q-PCR of the six cell lines (Figure 1A). Very low levels (<0.001 relative to control) of S100A9 were observed not only in all the ER⁺ cell lines but also in the TN MDA-MB-231 cell line. In contrast, a high level of S100A9 mRNA was found in MDA-MB-468 and SKBR3 cells (Figure 1A). A similar expression pattern could be seen at the protein level using IP with subsequent WB of cell lysates prepared from the cell lines (Figure 1B). IP was used as a weak background band and was present in all cell lysates at the size of S100A9 (14kDa; data not shown). We then proceeded with an IHC staining of S100A9 on paraffin-embedded cell pellets from the cell lines used (Figure 1C). The cytoplasmic IHC staining was intense in the two cell lines expressing S100A9 (SKBR3 and MDA-MB-468; Figure 1C, right and center). A membranous as well as a

Figure 2. S100A9 induced cytokine expression in human breast cancer cells in vitro. rS100A9 (10 μg ml⁻¹) induced (A) IL-8, (C) IL-6 and (E) IL-1β levels were measured using cytometric bead array (CBA) in supernatants from stimulated breast cancer cell lines as indicated. The relative expression of corresponding mRNA was measured using Q-PCR (B) IL-8, (D) IL-6 and (F) IL-1β. Error bars indicate s.e.m. *P<0.05, **P<0.01, ***P<0.001 using ANOVA test.
nuclear staining was seen in these S100A9-expressing cell lines (Figure 1C). We next silenced S100A9 in MDA-MB-468 cells using siRNA and verified the knockdown of S100A9 and the specificity of the IHC stainings using Q-PCR (Supplementary Figure S1A) and IHC of paraffin-embedded cells (Supplementary Figure S1B), respectively. To confirm the nuclear staining in the S100A9-expressing cells, we also performed nuclear lysates from MDA-MB-468 cells showing that S100A9 was present in both the cytosol and nucleus (Figure 1D).

Cytokine release is induced upon rS100A9 stimulation. The functional role for S100A9 in human breast epithelial cells is not clear (Arai et al., 2004, 2008; Moon et al., 2008; Yin et al., 2013; Cormier et al., 2014; Gumireddy et al., 2014). As S100A9 is known to induce inflammatory cascades in certain cell types, we wanted to investigate whether rS100A9 could do this in malignant epithelial breast cancer cells as well. Using rS100A9 in Ca²⁺/Zn⁺ physiological conditions has previously been shown to trigger a conformational change of S100A9 (Björk et al., 2009; Markowitz and Carson, 2013). We therefore added rS100A9 in Ca²⁺/Zn²⁺-high conditions and analysed whether inflammatory cytokines were released upon S100A9 stimulation of breast cancer cell lines. Indeed, in one of the cell lines we found a significantly enhanced expression of the cytokines IL-8, IL-6 and IL-1β at both the protein level (Figure 2A, C and E) and mRNA level (Figure 2B, D and F) upon stimulation with rS100A9 homodimers. This was preferentially seen in MDA-MB-231 cells that lack endogenous expression of S100A9 (TN cell line) and to some extent in the MDA-MB-468 cells (TN EGFR⁺⁺). Stimulation with S100A9/A8 heterodimers did not induce this cytokine release (Supplementary Figure S1C). Interestingly, only very modest or no decrease in cytokine expression was seen when S100A9 was silenced in the S100A9-expressing cells (Supplementary Figure S1D).

S100A9 affects NFκB activity in breast cancer cells. To investigate whether the S100A9-induced cytokine release was caused by an S100A9-induced activation of NFκB activity, we performed NFκB Dual-Luciferase reporter assays. As shown in Figure 3A and B, addition of rS100A9 induced a significant NFκB activity in the MDA-MB-231 cell line but not the MDA-MB-468 or SKBR3 cell lines. Addition of S100A8/A9 heterodimers induced a modest but significant NFκB activity in the MDA-MB-231 cell line (Figure 3B) but as described above absolutely no increase in cytokine expression (Supplementary Figure S1C). The most logical explanation to this is that S100A8/A9-induced NFκB activity is too low for pro-inflammatory cytokine induction. We next performed

![Figure 3](image-url)

**Figure 3.** S100A9 induces NFκB in breast cancer cells in vitro in a TLR4-dependent manner. (A) Dual luciferase reporter assays of breast cancer cells transfected with a NFκB reporter. TK-Renilla was co-transfected as control. S100A9 was added to stimulate NFκB activity as described in Material and Methods. Error bars indicate s.e.m. *P<0.05 using Student’s t-test. (B) Dual luciferase reporter assays of MDA-MB-231 breast cancer cells transfected with a NFκB reporter. TK-Renilla was co-transfected as control. S100A9 (10 μg ml⁻¹) or rS100A8/A9 (10 μg ml⁻¹) was added to stimulate NFκB activity in MDA-MB-231 cells as described in Material and Methods. Error bars indicate s.e.m. *P<0.05 using Student’s t-test. (C) TLR4 and RAGE mRNA expression levels in human breast cancer cell lines as measured by Q-PCR. Error bars indicate s.e.m. ***P<0.001 using ANOVA test. (D) Dual luciferase reporter assays of breast cancer cells transfected with negative control (nc) siRNA or siRNA directed against TLR4 mRNA (si#1 and si#2) and subsequently stimulated with rS100A9 or rS100A8/A9 together with a NFκB reporter and TK-Renilla as control. Error bars indicate s.e.m. **P<0.01 using ANOVA test. (E) IL-8 protein levels in supernatants from MDA-MB-231 breast cancer cells transfected with negative control (nc) siRNA or siRNA directed against TLR4 mRNA (si#1 and si#2) and subsequently stimulated or not with rS100A9 homodimers. Cytometric bead array (CBA) was used to measure IL-8 levels. Error bars indicate s.e.m. *P<0.05, **P<0.01, ***P<0.001 using ANOVA test. (F) Dual luciferase reporter assays of MCF-7 breast cancer cells transfected with the MD2-hTLR4 complex (pDUO-MD2-hTLR4) together with a NFκB reporter and TK-Renilla as control. Error bars indicate s.e.m. **P<0.01 using ANOVA test. (G) EGFR induced S100A9 expression in human breast cancer cells in vitro. rEGF stimulation of indicated breast cancer cell lines induced S100A9 mRNA levels as measured using Q-PCR. Error bars indicate s.e.m. *P<0.05, **P<0.01, ***P<0.001 using ANOVA test.
a Q-PCR analysis of the potential receptors for Ca\(^{2+}\)-dependent S100A9 signalling: TLR4 and RAGE (Markowitz and Carson, 2013), and could show that only MDA-MB-231 cells expressed high levels of TLR4 (Figure 3C, left). RAGE was expressed at relatively similar levels (Figure 3C, right). As the S100A9-expressing cell lines SKBR3 and MDA-MB-468 cells did not express TLR4 (Figure 3C, left) but expressed RAGE at varying levels (Figure 3C, right), we next investigated the NFκB activity upon S100A9 silencing in SKBR3 and MDA-MB-468 cells (Figure 3D). Silencing of S100A9 did not promote a decreased NFκB activity in SKBR3 or MDA-MB-468 cells (Figure 3D). In line with this and as mentioned above, only very modest or no decrease in cytokine expression was seen when S100A9 was silenced in the S100A9-expressing cells that lack TLR4 or RAGE (Supplementary Figure S1D). We therefore performed a TLR4-silencing experiment and could show that the rS100A9-induced IL-8 release was decreased when TLR4 was silenced in MDA-MB-231 cells and subsequently treated with rS100A9 (Figure 3E). Also, introduction of the MD2-hTLR4 complex (pDUO-MD2-hTLR4) in otherwise MD2- and TLR4-negative MCF7 cells promoted a significant NFκB activity upon S100A9 stimulation (Figure 3F).

Because of the inherent expression of EGFR in MDA-MB-468 (amplified; EGFR \(^{++}\)) and SKBR3 (EGFR \(^{+}\)) cells, we also wanted to analyse whether EGF could induce S100A9 per se. Indeed, we found that rEGF induced S100A9 at the mRNA level in SKBR3 but not in the EGFR-amplified MDA-MB-468 cells (Figure 3G). In an attempt to investigate further functions of S100A9, we performed an array of in vitro experiments, including cell cycle, proliferation, apoptosis, actin polymerisation, epithelial-to-mesenchymal transition (EMT) and migration analyses. Using the mentioned breast cancer cell lines rS100A9 homodimers or siRNA towards S100A9,

![Figure 4](image-url)

**Figure 4.** Effects of S100A9 on breast cancer cell proliferation, survival and F-actin polymerisation in vitro. (A) Effects of rS100A9 on breast cancer cell proliferation using thymidine-3H incorporation (left) or WST-1 assay (right) on the different breast cancer cell lines indicated. (B) Breast cancer cell proliferation using thymidine-3H incorporation on cell lines transfected with either negative control (nc) or silencing (si) S100A9 siRNAs as indicated. Error bars indicate s.e.m. *P<0.05 using ANOVA test. (C) Breast cancer cell proliferation/viability using WST-1 assay (right) on cell lines transfected with either negative control (nc) or silencing (si) S100A9 siRNAs as indicated. Error bars indicate s.e.m. NS = not significant using ANOVA test. (D) Effects of S100A9 on F-actin polymerisation in MCF-7 cells using phalloidin IF (green) staining. Blue staining = DAPI.
S100A9 expression correlates with ER and PgR expression in primary breast cancers. We found a very strong negative correlation between expression of S100A9 mRNA with either ER (r-value = 0.518; P = 1.7e-25) and PgR (r-value = 0.468; P = 1.8e-20), and a positive correlation between expression of S100A9 mRNA with either ERBB2 (r-value = 0.238; P = 6.8e-06) or EGFR (r-value = 0.319; P = 9.6e-10) (Supplementary Figures S2A–D).

Following IHC treatment of our TMA comprising 144 breast cancers, cytoplasmic and nuclear S100A9 staining was successfully annotated in 129 (89.6%) tumours and 128 tumours (88.9%) for stromal compartment. In line with both the IHC data from breast cancer cell lines, as well as the gene expression profiling data, S100A9 expression (cytoplasmic, nuclear, membrane as well as stromal) was significantly associated with both ER and PgR expression. A threshold of 100 arbitrary staining units (ASU) (Figure 2A) for S100A9 expression was used to dichotomize expression in the breast cell lines. This level of staining was also used for the IHC analysis on the tumour cohort.

Table 1a. Correlations between S100A9 expression and clinicopathological features in primary breast cancer (N = 144)

<table>
<thead>
<tr>
<th>Clinicopathological features</th>
<th>S100A9 cytoplasmic</th>
<th>S100A9 nuclear</th>
<th>S100A9 membrane</th>
<th>S100A9 stroma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.040, 0.656, 129</td>
<td>-0.028, 0.752, 129</td>
<td>0.029, 0.47, 129</td>
<td>-0.026, 0.770, 128</td>
</tr>
<tr>
<td>Nodal stage</td>
<td>0.030, 0.747, 117</td>
<td>-0.048, 0.610, 117</td>
<td>-0.021, 0.822, 117</td>
<td>0.205, 0.028*, 116</td>
</tr>
<tr>
<td>Tumour size</td>
<td>0.017, 0.188, 129</td>
<td>0.037, 0.678, 129</td>
<td>0.097, 0.276, 129</td>
<td>0.257, 0.003**, 128</td>
</tr>
<tr>
<td>Ki67</td>
<td>0.213, 0.024*, 112</td>
<td>0.141, 0.138, 112</td>
<td>0.153, 0.108, 112</td>
<td>0.318, 0.001**, 111</td>
</tr>
<tr>
<td>Her2</td>
<td>0.078, 0.384, 126</td>
<td>0.064, 0.478, 126</td>
<td>0.117, 0.194, 126</td>
<td>0.211, 0.018*, 125</td>
</tr>
<tr>
<td>ER status</td>
<td>-0.306, 0.000**, 129</td>
<td>-0.296, 0.001**, 129</td>
<td>-0.348, 0.000**, 129</td>
<td>-0.346, 0.000**, 128</td>
</tr>
<tr>
<td>PR status</td>
<td>-0.231, 0.009**, 129</td>
<td>-0.215, 0.014*, 129</td>
<td>-0.336, 0.000**, 129</td>
<td>-0.283, 0.001**, 128</td>
</tr>
<tr>
<td>EGFR</td>
<td>0.171, 0.064, 118</td>
<td>0.014, 0.884, 118</td>
<td>0.140, 0.132, 118</td>
<td>0.099, 0.286, 117</td>
</tr>
<tr>
<td>Basal</td>
<td>0.316, 0.000**, 129</td>
<td>0.262, 0.003**, 124</td>
<td>0.291, 0.001**, 124</td>
<td>0.245, 0.006**, 123</td>
</tr>
<tr>
<td>Luminal A</td>
<td>-0.300, 0.001**, 122</td>
<td>-0.238, 0.008**, 122</td>
<td>-0.300, 0.001**, 122</td>
<td>-0.402, 0.000**, 121</td>
</tr>
<tr>
<td>Luminal B</td>
<td>0.003, 0.977, 123</td>
<td>-0.050, 0.584, 123</td>
<td>-0.024, 0.791, 123</td>
<td>0.178, 0.050*, 122</td>
</tr>
</tbody>
</table>

Abbreviations: EGFR = epidermal growth factor receptor; ER = oestrogen receptor; Her2 = human epidermal growth factor 2 receptor; PR = progesterone receptor. Shaded boxes are significant.*P<0.05; **P<0.01; ***P<0.001 using Spearmans Rho test.
stromal; Figure 5A–D) correlated to ER− PgR− hormone receptor status of the breast tumours (P<0.001; Tables 1a–c). Cytoplasmic S100A9 also correlated to expression of the Ki67 proliferation marker (Table 1a). Tumours presenting Her2 or EGFR positivity were relatively few (n = 12 and n = 11, respectively). Despite this, stromal S100A9 expression correlated to Her2 positivity (P = 0.018; Table 1a) and presented a borderline correlation to EGFR positivity (P = 0.064; Table 1a). All of the Her2+ (n = 12) as well as all EGFR+ (n = 11) showed cytoplasmic S100A9 expression (Table 1b).

**Stromal S100A9 expression correlates to the presence of anti-inflammatory CD163+ myeloid cells.** Tumour stromal S100A9 expression has previously been described in different tumours (e.g., prostate cancer) (Tidehag et al., 2014). In this study, we found that stromal S100A9 expression (predominantly in cells with a leukocyte morphology) correlated not only with ER− PgR− tumours as mentioned above but also to parameters such as larger tumour size and Ki67 positivity and nodal stage (Table 1a; S100A9 stroma; right). We have previously shown that anti-inflammatory CD163+ myeloid cells are located preferentially in the tumour stroma of TN breast cancer and also that this correlated to higher grade, larger tumour size and Ki67 positivity (Medrek et al., 2012). As shown in Table 1c, breast cancer stromal S100A9 correlated with anti-inflammatory CD163+ myeloid cells but interestingly not to the macrophage marker CD68. This suggests that the myeloid cells expressing S100A9 are of immature myeloid origin (e.g., MDSCs). Supporting this notion, also anti-inflammatory CD163+ myeloid cells in the tumour nest actually expressed S100A9, but CD68+ macrophages did not (Table 1c).

**S100A9 expression in breast cancer correlates with a poor survival.** S100A9 expression in cytoplasm and in stroma was found to be significantly associated with an impaired survival (Figure 5). The same trend but non-significant was seen for membrane and nuclear expression (data not shown). For cytoplasmic expression, CRT analysis revealed a cutoff at 0.149/3.00 (Supplementary Figure S3A) where patients having positive (any) S100A9 expression denoted as moderate–high had significantly impaired survival (n = 116/129, P = 0.021, Figure 5E). For stromal expression, CRT analysis that revealed an optimal cutoff at 1.95/3.00 (Supplementary Figure S3B) also had significantly impaired survival (P < 0.001, Figure 5F). This is in line with what we previously showed concerning correlation between impaired overall survival and the presence of macrophages and anti-inflammatory myeloid cells in the tumour stroma, with a preferential presence of anti-inflammatory myeloid cells in the tumour stroma of TN breast cancers particularly (Medrek et al., 2012).

### DISCUSSION

S100A9 expression in breast cancer has previously been explored in vitro and in small cohorts of patients (Arai et al., 2004; Cross et al., 2005; Arai et al., 2008; Moon et al., 2008; Markowitz and Carlson, 2013; Yin et al., 2013; Cormier et al., 2014; Guimiredy et al., 2014). Also, a large protein profiling study was performed on breast cancers (Goncalves et al., 2008) where cytoplasmic S100A9 expression in the malignant breast epithelial cells was investigated. Studies concerning the role for S100A9 in breast cancer cells in vitro are indefinite (Markowitz and Carlson, 2013) and one reason for this is the limited supply of reagents. As S100A9 acts as a chemo-attractant for certain immunosuppressive cells and is expressed in myeloid suppressor cells that are important in diseases such as cancer (Ostrand-Rosenberg and Sinha, 2009), we decided to perform a deeper analysis concerning the expression and localisation pattern of S100A9 and its correlation to the presence of different tumour-infiltrating myeloid cells. We stained TMA sections containing samples of 144 breast cancers using a carefully validated antibody towards human S100A9 and using a publicly available gene expression data set consisting of 351 primary breast tumours. The findings were endorsed by analysis regarding the functional role of S100A9 specifically using stimulation with rS100A9 or silencing of S100A9 in vitro.

Although S100A9 is expressed in some epithelial cell types and also in certain cancers, its functional role in these cell types is still obscure (Markowitz and Carlson, 2013). Our in vitro experiments regarding cell cycle analysis, apoptosis, migration and EMT markers, using stimulation with rS100A9 or silencing of S100A9, did not yield consistent results. However, as published previously, both cell proliferation and β-actin polymerisation was affected slightly by S100A9 in some cell lines and should therefore be warranted more studies in the future (Yin et al., 2013; Cormier et al., 2014). Instead we found that inflammatory cytokines were released upon S100A9 stimulation of breast cancer cell lines but only in cells with a high expression of TLR4 (MDA-MB-231), similar to what has previously been published regarding myeloid cells (Riva et al., 2012). In line with this, only very modest or no decrease in cytokine expression was seen when S100A9 was

| Table 1b. S100A9 expression in Her2-cutoff group (upper) and EGFR-cutoff group (lower): all Her2− and EGFR+ cases also express S100A9 |
|---|---|---|
| **S100A9 cytoplasmic** | 0 | 1 |
| Her2 cutoff | Total |
| 0 | 4 | 106 | 110 |
| 1 | 0 | 12 | 12 |
| Total | 4 | 118 | 122 |
| EGFR cutoff | Total |
| 0 | 3 | 104 | 107 |
| 1 | 0 | 11 | 11 |
| Total | 3 | 115 | 118 |

Abbreviations: EGFR – epidermal growth factor receptor; Her2 – human epidermal growth factor 2 receptor.

| Table 1c. Correlations between S100A9 expression and myeloid cell markers (CD68 and CD163) in primary breast cancer (N=144) |
|---|---|---|---|---|
| Presence of myeloid cells | S100A9 cytoplasmic | S100A9 nuclear | S100A9 membrane | S100A9 stroma |
| | Correlation coefficient, P value, N (two-tailed) | Correlation coefficient, P value, N (two-tailed) | Correlation coefficient, P value, N (two-tailed) | Correlation coefficient, P value, N (two-tailed) |
| CD68 tumour nest | 0.176, 0.079, 101 | 0.055, 0.588, 101 | 0.008, 0.939, 101 | 0.161, 0.109, 100 |
| CD68 tumour stroma | −0.070, 0.484, 101 | 0.022, 0.827, 101 | 0.050, 0.620, 101 | 0.059, 0.563, 100 |
| CD163 tumour nest | 0.130, 0.183, 107 | 0.133, 0.173, 107 | 0.162, 0.095, 107 | 0.209, 0.032*, 106 |
| CD163 tumour stroma | 0.074, 0.439, 112 | −0.068, 0.471, 112 | 0.080, 0.403, 112 | 0.197, 0.038*, 111 |

Shaded boxes are significant. *P<0.05, **P<0.01, ***P<0.001 using Spearman’s Rho test.
silenced in the S100A9-expressing cells that lack TLR4 or RAGE. Only, S100A9 signalling, but not S100A9/S100A8, induced significant expression of inflammatory proteins. Indeed, S100A9 homodimers but not S100A9/S100A8 heterodimers have been proposed to signal via TLR4 in a Ca2+/dependent manner (Markowitz and Carson, 2013). As both membranous and vesicular TLR4 has been reported in cancer cells, the cytoplasmic S100A9 expression pattern could represent intracellular as well as extracellular signalling pathways (Hassan et al, 2006).

Breast tumours of the TN and ER−PgR− subtypes most often express pro-inflammatory proteins that activate STAT3 (Sasser et al, 2007). STAT3 has previously been shown to induce S100A9 (Li et al, 2004; Lee et al, 2012). This does, however, not reflect the expression pattern of S100A9 in breast cancer cell lines in vitro, as a high S100A9 expression is seen only in two out of three ER−PgR− breast cancer cell lines tested. Hence other explanations as to why S100A9 is expressed in malignant epithelial breast cells are likely to be found in the future. A link between S100A9 expression and EGFR has been suggested for other cancer types before (Kim et al, 2011, 2014). The fact that the two cell lines expressing S100A9 both expressed EGFR (MDA-MB-468, EGFR+/− amplified; SKBR3, EGFR+/+ ) led us to the finding that also rEGF could induce S100A9 expression but only in EGFR-non-amplified SKBR3 cells. It would be interesting to investigate whether the tumour microenvironment as such could affect S100A9 expression in vivo.

After careful validation, we considered the S100A9 antibody used in this study to be specific using IHC on paraffin-embedded samples. We found that S100A9 was expressed primarily in tumours with an ER−PgR− phenotype. This correlation was found irrespective of the localisation of S100A9 (cytoplasmic, nuclear, membrane) in the malignant cells and was supported by a strong inverse correlation of the genes in a gene expression profile analysis made of 351 breast tumours (R2: microarray analysis and visualisation platform (http://r2.amc.nl; Tumour breast EXPOnet-351). Even stromal expression of S100A9 correlated not only with the ER− PgR− breast cancer phenotype but also to parameters such as larger tumour size, Her2 positivity and nodal stage. Stromal expression of S100A9 was mostly present in cells with a leukocyte morphology and correlated with the presence of anti-inflammatory myeloid cells (CD163+/−), but not with the macrophage marker CD68, in the same tumours. This support previous findings that S100A9 expression was mostly present in cells with a leukocyte morphology and correlated with the presence of anti-inflammatory myeloid cells (CD163+/−), but not with the macrophage marker CD68, in the same tumours. This support previous findings that S100A9 expression was mostly present in cells with a leukocyte morphology and correlated with the presence of anti-inflammatory myeloid cells (CD163+/−), but not with the macrophage marker CD68, in the same tumours. In this context, it is interesting to note that we previously have shown that anti-inflammatory myeloid cells (CD163+/−) are preferentially enriched in the stromal areas of breast tumours of the TN subtype. Cytoplasmic S100A9 expression did not, however, correlate to Her2 in our breast cancer cohort. Instead we found that, out of the 11 Her2+ tumours, all (100%) expressed cytosolic S100A9 in the malignant cells. The same was true for EGFR+ tumours (n = 12). The fact that no correlation can be found between S100A9 expression and Her2 or EGFR positivity is most likely due to the small amount of tumours with this particular subtype. This is supported by the gene expression profile analysis that showed a strong positive correlation between S100A9 and either ERBB2 (Her2) or EGFR at the gene expression level, as well as our in vitro analysis of breast cancer cell lines with this phenotype. A link between S100A9 expression and EGFR has previously been published regarding bladder cancer (Kim et al, 2011, 2014). Our findings that S100A9 expression correlates to ER−PgR− and Her2+ or EGFR+ breast tumours is also supported by a large protein profiling study performed on breast cancers (Goncalves et al, 2008).

The effect of S100A9 expression on primary breast cancer patient survival has not been studied in depth before, but the expression of S100A9 in metastatic lesions has been shown to correlate with a worse prognosis (Acharyya et al, 2012) and cytoplasmic S100A9 expression in malignant breast epithelial cells was correlated to worse overall survival, although it was concluded that this might be due to its correlation with other parameters such as grade, ER or ERBB2 status (Goncalves et al, 2008). In our study, patients having positive (any) cytoplasmic S100A9 expression were found to have a significant reduction in overall survival, where the main discrepancy was seen for patients having a minor increase in expression, and this was also seen for ER− PgR− tumours. Even more accentuated, a similar trend was seen for stromal S100A9 expression, where a higher expression was progressively associated with a reduced overall survival. This result fits very well to what was found when we analysed the presence of stromal CD163+ anti-inflammatory myeloid cells previously, again indicating that stromal S100A9 expression is caused by myeloid cells primarily (Medrek et al, 2012). In summary, this suggests that S100A9 can be expressed both in malignant cells and in myeloid cells in breast tumours. It is most likely so that S100A9 might have different roles for these cell types, but according to this study also similar functions are expected. This would primarily concern induction of an inflammatory environment. When the chemo-attractive effects on MDSCs are added to these processes, it is not surprising that both a stromal as well as malignant S100A9 expression pattern will affect breast cancer patient’s overall survival. With these data, we propose that S100A9 would be a good future candidate drug target for patients with ER−PgR− breast cancer, especially in patients with tumours that express Her2 or EGFR.

ACKNOWLEDGEMENTS

We thank Ms. Elise Nilsson for professional technical skills in preparation of TMAs and IHC. This work was supported by grants from the Swedish Research Council, The Swedish Cancer Foundation, Kocks Stiftelse, Osterlunds Stiftelse, Gunnar Nilsson Cancer Foundation, MAS Cancer Foundation and Åke Winberg's Foundation.

CONFLICT OF INTEREST

TL is a part-time employee at Active Biotech that develops S100A9 inhibitors for the treatment of autoimmune diseases and cancer.

REFERENCES


Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)